- selective slow inactivation of voltage-gated sodium channels
- modulation of collapsin response mediator protein-2
Developed to treat partial-onset epilepsy and painful diabetic neuropathy. Does not seem to work in this second postulated indication for more than a few months. May be freer of drug interactions than many other anticonvulsants and can be given easily iv as well as orally.
As a second anti-epileptic drug and as above.
- Oral in range 400 to 600mg tital dose daily
- iv seems to be well tolerated
Cautions and Interactions
- Elimination half-life about 13 hours
- linear, dose-proportional pharmacokinetics with low intrapatient and interpatient variability
- ↑ Ziegler D, Hidvégi T, Gurieva I, Bongardt S, Freynhagen R, Sen D, Sommerville K. Efficacy and Safety of Lacosamide in Painful Diabetic Neuropathy. Diabetes care. 2010 Jan 12.(Epub ahead of print) (Link to article – subscription may be required.)
- ↑ Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia. 2008 Mar; 49(3):418-24.(Link to article – subscription may be required.)